DSM and LibraGen sign agreement to co-develop transaminases for production of chiral amines
DSM and LibraGen announced that they have signed an agreement to co-develop new omega-transaminases for production of chiral amines. Under the terms of the partnership, LibraGen will use its proprietary enzyme discovery and development to identify new enzymes for efficient conversion of a large spectrum of ketons into optically pure R- and S-amines, a compound class highly relevant for fine chemicals and pharmaceuticals industries.
DSM will produce the enzymes at industrial scale using DSM's fermentation capabilities and proprietary expression platform, PluGbug(TM). LibraGen will sell the enzymes in kit form and both parties will use them for screening activities and the development of biocatalytic processes for third parties.
"This collaboration with LibraGen grows the number of available large-scale biocatalysts and will contribute to increasing competitiveness of the transaminase technology for production of chiral amines" said Oliver May, Competence Manager Biocatalysis at DSM Pharmaceutical Products. "In addition, by combining LibraGen's enzyme discovery and DSM's manufacturing capabilities the development timelines from enzyme discovery and screening to final product delivery to our customers will be significantly reduced" said Ronald Gebhard, R&D Director at DSM Pharmaceutical Products.
Financial details of the collaboration were not disclosed.
Most read news
Organizations
Other news from the department business & finance

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

“Rainbow color maps are pretty, but not suitable for science” - Researchers show distorted representation and perception of scientific results with colorful graphics and suggest alternatives
Emerson selected as main instrumentation provider for automation of Lucite International chemical plant in Singapore
LANXESS expanding water treatment unit at Uerdingen pigment facility
Bayer expands Polymer Research & Development Center facility in Shanghai
The Nobel Prize in Physics 2009 - The Royal Swedish Academy of Sciences has decided to award the Nobel Prize in Physics for 2009 with one half to Charles K. Kao and the other half jointly to Willard S. Boyle and George E. Smith
3M Expands its Medical Diagnostics Platform with Acquisition of Acolyte Biomedica Ltd.
IChemE welcomes UK fracking go-ahead
Merck KGaA: Intention to close Lacassagne R&D and production site in Lyon, France - Pre-clinical research in France to be concentrated in Chilly-Mazarin
